These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 16312453

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of oxacillin, vancomycin and teicoplanin against staphylococci isolated from patients on surgical and coronary intensive care units.
    Kucukates E, Nalan Karayel E, Gultekin N, Okuyan E, Kansiz E, Gurler N.
    Int J Antimicrob Agents; 2004 Aug; 24(2):193-4. PubMed ID: 15288323
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening.
    Nunes AP, Teixeira LM, Iorio NL, Bastos CC, de Sousa Fonseca L, Souto-Padrón T, dos Santos KR.
    Int J Antimicrob Agents; 2006 Apr; 27(4):307-15. PubMed ID: 16542825
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.
    Goldstein FW, Atoui R, Ben Ali A, Nguyen JC, Ly A, Kitzis MD.
    Clin Microbiol Infect; 2004 Apr; 10(4):342-5. PubMed ID: 15059127
    [Abstract] [Full Text] [Related]

  • 11. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin].
    Gil M, Otth L, Wilson M, Arce E, Zaror A, Lizama V.
    Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.
    Vignaroli C, Biavasco F, Varaldo PE.
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2577-82. PubMed ID: 16801450
    [Abstract] [Full Text] [Related]

  • 14. Emergence of vancomycin-intermediate Staphylococcus species in southern India.
    Menezes GA, Harish BN, Sujatha S, Vinothini K, Parija SC.
    J Med Microbiol; 2008 Jul; 57(Pt 7):911-912. PubMed ID: 18566156
    [No Abstract] [Full Text] [Related]

  • 15. [Heterogeneity of Brain Heart Infusion agar media (BHI): effects on the determination of the vancomycin and the teicoplanin minimal inhibitory concentrations (MIC) of Staphylococcus aureus strains].
    Martin C.
    Pathol Biol (Paris); 2004 Oct; 52(8):450-4. PubMed ID: 15465263
    [Abstract] [Full Text] [Related]

  • 16. Teicoplanin resistance in Staphylococcus haemolyticus is associated with mutations in histidine kinases VraS and WalK.
    Vimberg V, Cavanagh JP, Benada O, Kofroňová O, Hjerde E, Zieglerová L, Balíková Novotná G.
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):233-240. PubMed ID: 29246777
    [Abstract] [Full Text] [Related]

  • 17. Nosocomial spread of linezolid-resistant Staphylococcus haemolyticus infections in an intensive care unit.
    Rodríguez-Aranda A, Daskalaki M, Villar J, Sanz F, Otero JR, Chaves F.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):398-402. PubMed ID: 19232856
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF, Sarmiento I, Moeck G.
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.